The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2013: Volume 18/ Issue 38 Article 1
Back to Table of Contents
Download (pdf)

Eurosurveillance, Volume 18, Issue 38, 19 September 2013
Rapid communications
Insidious reintroduction of wild poliovirus into Israel, 2013
  1. The Division of Epidemiology, Public Health Services, Ministry of Health, Jerusalem, Israel
  2. Public Health Services, Ministry of Health, Jerusalem, Israel
  3. Braun School of Public Health and Community Medicine, Hebrew University Hadassah Faculty of Medicine, Jerusalem, Israel
  4. These authors contributed equally to this study
  5. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
  6. Central Virology Laboratory, Public Health Services, Ministry of Health, The Chaim Sheba Medical Centre, Tel Hashomer, Israel
  7. Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
  8. South District Health Office, Ministry of Health, Beer Sheva, Israel
  9. Ministry of Health, Jerusalem, Israel

Citation style for this article: Anis E, Kopel E, Singer SR, Kaliner E, Moerman L, Moran-Gilad J, Sofer D, Manor Y, Shulman LM, Mendelson E, Gdalevich M, Lev B, Gamzu R, Grotto I. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 2013;18(38):pii=20586. Article DOI:
Date of submission: 09 September 2013

Israel was certified as polio-free country in June 2002, along with the rest of the World Health Organization European Region. Some 11 years later, wild-type polio virus 1 (WPV1) was isolated initially from routine sewage samples collected between 7 and 13 April 2013 in two cities in the Southern district. WPV1-specific analysis of samples indicated WPV1 introduction into that area in early February 2013. National supplementary immunisation with oral polio vaccine has been ongoing since August 2013.

Detection of wild poliovirus in Israel

Wild poliovirus type 1 (WPV1) was isolated from routine samples collected during epidemiological week 15 (7 to 13 April 2013) in sewage treatment facilities in Beer Sheva and Rahat, two cities in Israel’s Southern district. Beer Sheva, the regional commercial centre, has a population of about 200,000. It is situated 20 km south of Rahat and there is considerable population movement and commerce between the two cities.


Poliomyelitis (polio) has been a notifiable disease in Israel since 1951. WPV1 predominated during the large, pre-vaccine national epidemics during 1949 to 1956 [1,2] with a peak incidence of 129.4 cases per 100,000 of the general (mostly Jewish) population in 1950 [1]. Substantial control of polio was achieved by the mid-1960s (0.1 per 100,000 in 1965) through universal childhood vaccination with trivalent oral polio vaccine (OPV), followed by low-level activity throughout the 1970s (0.2-0.9 per 100,000), particularly in the Jewish population (0.1 per 100,000 Jewish population). Annual campaigns with type 1 monovalent OPV further reduced polio incidence also among the non-Jewish population in the 1980s (0.1 to 0.3 per 100,000 non-Jewish population) [1].

Israel has not had a polio case since an outbreak in 1988, in which 15 poliovirus-infected people had paralytic polio, mostly in the Hadera sub-district in the northern part of the country [1,3], following importation of WPV1 from northern Egypt the year before the outbreak [1,4]. Most of the 1988 outbreak cases had received OPV in the past. A mass trivalent OPV vaccination campaign ended the outbreak [3].

In 1990, a routine national vaccine programme – combining three inactivated polio vaccine (IPV) doses with three trivalent OPV doses – was implemented. This schedule continued until 2005, when OPV was discontinued three years after the polio-free status certification by the World Health Organization (WHO), in June 2002 [1]. The IPV-only schedule since 2005 prescribes three IPV doses by the age of six months with two additional booster doses at 12 months and at seven years (second elementary grade) (Table 1). The 2012 national IPV3 coverage was 95% [5].

Table 1. Historical and current routine childhood vaccine schedules against poliomyelitis, Israel, 1957–2013*

Israel has maintained a routine environmental polio surveillance programme since 1988, through monthly sampling of eight to 10 sewage treatment facilities in largely populated areas or areas considered sentinels of risk for importation of WPV, such as Rahat, a major Bedouin city, which was the initial importation locus of the 1988 WPV1 outbreak [4]. Additionally, since 1996, notification of cases with acute flaccid paralysis (AFP) up to the age of 15 years has been mandated by law and active AFP surveillance has been implemented. Since then, the level of reporting fluctuated, sometimes below the WHO threshold (1 case of AFP per 100,000 population <15 years of age). As a consequence, the structure of the active AFP surveillance system was reorganised several times in the past years, and since January 2013, the national Division of Epidemiology contact directly, on a weekly basis, each representative of the relevant clinical care units in the country, in order to obtain the complete information on any suspected AFP cases, and assuring the required clinical sampling for the necessary laboratory tests.

Here we describe the epidemiology of the reintroduction of WPV1 into Israel in 2013, a potential public health emergency at the national level and public health threat at the global level.

Epidemiological investigation

Environmental surveillance
As part of the regular environmental surveillance, sewage samples are processed at the Central Virology Laboratory in Tel Hashomer. Poliovirus is isolated from the samples by infecting recombinant mouse cell line L20B according to WHO guidelines [6,7]. Individual plaques propagated in tube cultures are then analysed by real-time polymerase chain reaction (PCR) using United States (US) Centers for Disease Control and Prevention (CDC) analytical kits designed for identification of polioviruses and differentiation between vaccine and wild types [8], followed by characterisation by genome sequencing [9].

The samples collected in the sewage treatment facilities of Rahat and Beer Sheva are part of this routine environmental surveillance. At the end of May 2013, the Central Virology Laboratory confirmed that WPV1 had been detected in two sewage samples taken in the Rahat and Beer Sheva facilities in epidemiological week 15 (7-13 April 2013).

A WPV1-specific analysis of samples from early 2013 indicated WPV1 introduction into Beer Sheva in February 2013 (week 6, 3-9 February) and into Rahat in March 2013 (week 11, 10-16 March). The isolates from Rahat and Beer Sheva were identified as non-Sabin poliovirus type 1 belonging to the SOAS (South Asia) lineage of WPV1, which has been circulating in Pakistan in recent years, and which was also isolated from sewage samples in the Cairo region, Egypt, in December 2012 [10].

Intensified environmental surveillance
Subsequently, environmental surveillance was extended and intensified to cover more sewage sampling sites nationally. As of 1 September 2013, WPV1 has been detected in 87 of 220 samples tested that were obtained from 79 sewage sampling sites in Israel and collected after 3 February 2013 (Figure). In the southern district, most of the treatment facilities with samples that have been continuously WPV1 positive to date have been in areas inhabited by Bedouin communities. WPV1 was also detected in several sewage sampling sites in central Israel, mostly around Arab or mixed Jewish–Arab communities, indicating countrywide transmission.

Figure. Locations of sewage samples positive for wild poliovirus type 1 identified through environmental surveillance, Israel, by district, 3 February–12 September 2013

Public health response from end May to 5 August 2013

The following instant actions were carried out, following the detection of WPV1 in Israel.

  • In Rahat and the surrounding area, where substantial and continuous WPV1 circulation has been detected in samples collected since the first quarter of 2013, an IPV catch-up vaccination campaign was initiated in order to maximise the routine childhood IPV coverage and to administer a booster IPV to all adults who had no evidence of prior booster vaccination in adulthood (i.e. before travel to polio endemic countries), with special outreach to sewage facility workers and migrant communities whose members had migrated through Egypt since 2007 [11].
  • A national hygiene campaign was initiated to raise public awareness of wild poliovirus circulation and hand-washing and personal hygiene and in preparation for a widespread OPV supplementary immunisation activity.
  • In order maximise OPV coverage, professional information concerning poliovirus and vaccination was made available to physicians throughout the country as well as to the public, using diverse communication channels – traditional media, social media, and the Internet [12].

Enhanced surveillance of acute flaccid paralysis

After the isolation of WPV1 in sewage, surveillance for AFP was expanded in June 2013, to include all age groups.

From 1 January 2013 to 1 September 2013, 45 cases of AFP had been actively detected, of which, 17 were children <15 years of age. Three of these children were defined as 'hot' cases (i.e. lacking a complete series of routine childhood IPV immunisation due to young age or parental objection) [13]. The estimated annual AFP incidence in 2013, based on cases detected so far, is 1.15 cases per 100,000 population <15 years of age. All 45 AFP cases tested negative for WPV1.

No case of paralytic polio has been detected to date in Israel.

Start of aseptic meningitis surveillance
National aseptic meningitis surveillance was also initiated in June 2013. As of 28 August 2013, a total of 156 cases of aseptic meningitis were reported nationally: none was positive for poliovirus; 65 cases (42%) were positive for other non-polio enteroviruses.

Ongoing national supplementary immunisation activity
A supplementary immunisation activity using bivalent OPV [14,15] was initiated in the Southern district on 5 August 2013 and has been expanded nationally since 18 August, with the objective of rapidly interrupting WPV1 transmission across the country, particularly in children previously vaccinated according to the IPV-only programme, by inducing effective intestinal immunity [16,17].

All children born after 1 January 2004, who have received at least one dose of IPV in the past, were considered vaccine candidates. This approach is in accordance with that used in the routine national immunisation schedule during 1990 to 2004, which has a formidable international safety profile [18]. Vaccine candidates who have immunodeficiency conditions or those living with immunocompromised household contacts are not vaccinated with bivalent OPV.

As of 15 September 2013, approximately 750,000 of about 1,200,000 eligible bivalent OPV candidates (63%, inter-district range: 45–83%) were vaccinated nationwide (Table 2).

The Israeli response to the finding of WPV1 has been fully coordinated with leading local epidemiology, infection disease and paediatric experts, as well as WHO and the US CDC. A joint WHO/CDC mission visited Israel in June 2013 and its experts have been consulted at every stage of the outbreak response.

Table 2. Bivalent oral polio vaccine coveragea,b, by district, since the start of the supplementary immunisation activity on 5 August 2013, Israel


The last widespread circulation of wild poliovirus in Israel was 25 years ago, resulting in a national outbreak with cases of permanent paralytic polio [3]. The major difference between the 1988 outbreak in Israel and other outbreaks of wild poliovirus infection in recent years in other developed countries [19,20] that used an IPV-only routine vaccination schedule, is the early detection of silent virus circulation through an existing early warning system, involving national environmental surveillance. This early detection allowed for further investigation and planning of a national response well in time.

An apparent single event of long-distance WPV1 importation from Pakistan, where the SOAS genotype has circulated in 2012, to Egypt, possibly by an asymptomatic carrier or carriers, and the further importation to Israel – a journey of thousands of kilometres – has resulted in nearly nationwide WPV1 spread. This widespread WPV1 circulation might have been facilitated by the substantial non-OPV immunised cohort of children, who were born after the withdrawal of routine OPV doses from the national immunisation programme in 2005.

Notably, the highly probable chain of events that lead to the re-introduction of WPV1 into Israel in 2013 is not the first of its kind. Other possible long-distance point importations into decades-long polio-free countries were identified, in Finland and the Netherlands, following the paralytic polio outbreaks of 1986 and 1992, respectively [19-22]. This is in contrast to the endemic, Middle-Eastern origin of the 1988 outbreak due to WPV1 in Israel [1,3,4].

The detection of WPV1 in 2013 in Israel should therefore alert polio-free countries and global health organisations, which could confront a similar situation, given the increased mobility of people and populations, as long as wild poliovirus continues to be endemic in several parts of the world. Furthermore, our findings are also relevant to the global debate related to polio preventive measures such as routine national environmental surveillance and reinstitution of combined IPV and OPV routine immunisation schedule, even in polio-free countries with high IPV coverage [23].

We thank the following individuals for their contributions (by surname alphabetical order): Elran Bella, Prof. Engelhard Dan, Honovich Mira, Prof. Leventhal Alex, Dr. Levine Hagai, Prof. Linder Nehama, Prof. Rahav Galia, Dr. Rubin Lisa, Prof. Rishpon Shmuel, Prof. Shalit Itamar, Prof. Shohat Tami, Dr. Slater Paul, Prof. Somekh Eli, Dr. Tasher Diana. We also thank the joint WHO/CDC mission.

Conflict of interest
None declared.

Authors’ contributions
Emilia Anis, Eran Kopel, Shepherd R. Singer and Itamar Grotto wrote the first draft of the manuscript. All authors revised and approved the final version of the manuscript.

* Authors' correction
In the last row of Table 1, ’16 years’ was corrected to ’13 years’. This correction was made on 18 November 2013 at the request of the authors.


  1. Swartz TA. The epidemiology of polio in Israel. An historical perspective. Israel Center for Disease Control (ICDC), Ministry of Health; Tel Aviv: Nov 2008. Publication 317. Available from:
  2. Yekutiel P, Levinger EL, Muhsam HV, Yekutiel MP. Poliomyelitis outbreak in Israel, 1950-1. Bull World Health Organ. 1955;12(4):651-76. PMid:14379003. PMCid:PMC2542293.
  3. Slater PE, Orenstein WA, Morag A, Avni A, Handsher R, Green MS, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet. 1990;335(8699):1192-5; discussion 1196-8.
  4. Shulman LM, Handsher R, Yang CF, Yang SJ, Manor J, Vonsover A, et al. Resolution of the pathways of poliovirus type 1 transmission during an outbreak. J Clin Microbiol. 2000;38(3):945-52. PMid:10698978. PMCid:PMC86309.
  5. World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system. 2013 global summary. Geneva: WHO. [Accessed 1 Sep 2013]. Available from:
  6. World Health Organization (WHO). Polio laboratory manual. 4th ed. Geneva: WHO; 2004. WHO/IVB/04.10. Available from:
  7. Manor Y, Blomqvist S, Sofer D, Alfandari J, Halmut T, Abramovitz B, et al. Advanced environmental surveillance and molecular analyses indicate separate importations rather than endemic circulation of wild type 1 poliovirus in Gaza district in 2002. Appl Environ Microbiol. 2007;73(18):5954-8. PMid:17660306. PMCid:PMC2074904.
  8. Kilpatrick DR, Yang CF, Ching K, Vincent A, Iber J, Campagnoli R, et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol. 2009;47(6):1939-41. PMid:19386844. PMCid:PMC2691077.
  9. Kilpatrick DR, Iber JC, Chen Q, Ching K, Yang SJ, De L, et al. Poliovirus serotype-specific VP1 sequencing primers. J Virol Methods. 2011;174(1-2):128-30. PMid:21440569. 
  10. ProMED-mail. Poliomyelitis - worldwide (01): Egypt ex Pakistan, Niger. Archive Number 20130122.1509210. 22 Jan 2013. Available from:
  11. The Knesset Research and Information Center. [The management of infiltrators from the Egyptian border]. 26 May 2010. [Hebrew]. Available from:
  12. Ministry of Health (MoH). Supplemental polio vaccination campaign. "Two Drops" – the national supplementary immunisation activity official website. Jerusalem: MoH. [Accessed 1 Sep 2013]. Available from:
  13. World Health Organization (WHO). Guidelines on responding to the detection of wild poliovirus in the WHO European Region. Copenhagen: WHO; 2007. Available from:
  14. World Health Organization (WHO). WHO package insert. Polio Sabin™ One and Three (oral). WHO model insert (June 09). GlaxoSmithKline Biologicals. Bivalent Oral Poliomyelitis Vaccine Types 1 and 3 (bOPV). Geneva: WHO. [Accessed 1 Sep 2013]. Available from:
  15. Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376(9753):1682-8.
  16. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599. PMid:22532797. PMCid:PMC3330118.
  17. Swartz TA, Green MS, Handscher R, Sofer D, Cohen-Dar M, Shohat T, et al. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. Vaccine. 2008;26(8):1083-90. PMid:18241962. 
  18. World Health Organization (WHO). Scientific evidence in support of: Note for the record: 5th meeting of the SAGE Working Group, World Health Organization, Geneva, September 3-4, 2012. Geneva: WHO; 2012. Available from:
  19. Oostvogel PM, van Wijngaarden JK, van der Avoort HG, Mulders MN, Conyn-van Spaendonck MA, Rümke HC, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet. 1994;344(8923):665-70.
  20. Hovi T, Cantell K, Huovilainen A, Kinnunen E, Kuronen T, Lapinleimu K, et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet. 1986;1(8495):1427-32.
  21. Pöyry T, Kinnunen L, Kapsenberg J, Kew O, Hovi T. Type 3 poliovirus/Finland/1984 is genetically related to common Mediterranean strains. J Gen Virol. 1990;71(Pt 11):2535-41. PMid:1701473. 
  22. Simonen ML, Roivainen M, Iber J, Burns C, Hovi T. Outbreak of poliomyelitis in Finland in 1984-85 - Re-analysis of viral sequences using the current standard approach. Virus Res. 2010;147(1):91-7. PMid:19883702. 
  23. Tulchinsky TH. Polio eradication: end-stage challenges. Bull World Health Organ. 2005;83(2):160. PMid:15744411. PMCid:PMC2623815.  

Back to Table of Contents
Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.